2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13D.03 Prognostic Factors of First-Line Immune Checkpoint Inhibitors in Combination with Chemotherapy in Extensive-Stage Small Cell Lung Cancer

EP.13D.03 Prognostic Factors of First-Line Immune Checkpoint Inhibitors in Combination with Chemotherapy in Extensive-Stage Small Cell Lung Cancer

Back to course

Pdf Summary

The document examines prognostic factors in the treatment of extensive-stage small cell lung cancer (ES-SCLC) using first-line immune checkpoint inhibitors (ICIs) combined with chemotherapy (etoposide plus platinum, EP). Conducted at Taipei Veterans General Hospital in Taiwan, the study involved a retrospective review of ES-SCLC patients treated between January 2012 and December 2021.<br /><br />Key findings from the study suggest that combining ICIs with EP leads to improved overall survival compared to EP alone. Patients receiving ICIs showed a median overall survival advantage. However, liver metastasis emerged as a poor prognostic factor affecting patient outcomes negatively. Additionally, a neutrophil to lymphocyte ratio (NLR) of 4 or more and severe hematological adverse events were associated with reduced overall survival in patients undergoing ICI-EP therapy.<br /><br />The study also highlights the beneficial impact of consolidative thoracic radiotherapy on progression-free survival (PFS). It shows that thoracic radiotherapy, when used alongside systemic ICI-EP treatment, might positively influence patient outcomes.<br /><br />Data on adverse events indicate that while ICIs can offer survival benefits, they also present risks of significant hematological complications. Treatment-related side effects need careful management, especially in patients with severe hematological adverse events.<br /><br />Conclusively, ICIs combined with EP can enhance treatment efficacy but require careful consideration of individual patient factors, such as liver metastasis and blood cell ratios, to predict and manage potential outcomes and adverse reactions effectively. The study underscores the need for further real-world data to establish clear guidelines for the use of ICIs in ES-SCLC patients, especially considering the limited existing data on their efficacy and toxicity in Taiwanese populations.

Asset Subtitle

Ying-Ting Liao

Meta Tag

Speaker Ying-Ting Liao

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

extensive-stage small cell lung cancer

immune checkpoint inhibitors

chemotherapy

etoposide plus platinum

Taipei Veterans General Hospital

overall survival

liver metastasis

neutrophil to lymphocyte ratio

thoracic radiotherapy

adverse events